论文部分内容阅读
目的探讨前列腺癌(PCa)患者和前列腺增生(BPH)症患者血清中骨保护素(OPG)浓度的差异以及前列腺癌患者骨保护素浓度与血清前列腺特异性抗原(PSA)水平、前列腺体积是否具有相关性。方法采用双抗体夹心酶免法(ELISA)测定40例前列腺癌患者及40例前列腺增生患者血清OPG浓度,同时采集PCa患者的前列腺体积及PSA值。比较PCa患者及BPH患者血清OPG浓度的差异以及前列腺癌患者中OPG浓度与PSA、前列腺体积之间有无相关性。结果 PCa患者的血清OPG浓度平均值水平〔(14 900.19±5 168.65)pg/mL〕显著高于BPH组〔(10 457.87±4 786.29)pg/mL〕,差异有显著性意义(P<0.01)。PCa患者血清OPG浓度与PSA值及前列腺体积之间均无明显相关性(r分别为=0.221、0.138,P均>0.1)。结论血清OPG浓度对鉴别PCa和BPH有重要临床价值,PCa患者血清OPG浓度与血清PSA值及前列腺体积无明显相关性。
Objective To investigate the difference of serum osteoprotegerin (OPG) levels in patients with prostate cancer (PCa) and benign prostatic hyperplasia (BPH) and whether the serum prostate specific antigen (PSA) level and serum osteoprotegerin level in prostate cancer patients have prostate Correlation. Methods Serum OPG concentrations in 40 patients with prostate cancer and 40 patients with benign prostatic hyperplasia were measured by ELISA. The volume of prostate and PSA in PCa patients were also collected. To compare the differences of serum OPG concentrations in patients with PCa and BPH and the correlation between OPG concentration and PSA and prostate volume in patients with prostate cancer. Results The mean level of serum OPG concentration in PCa patients 〔(14 900.19 ± 5 168.65) pg / mL〕 was significantly higher than that in BPH group 〔(10 457.87 ± 4 786.29) pg / mL〕, the difference was statistically significant (P0.01) . PCa patients with serum OPG concentration and PSA value and prostate volume were no significant correlation (r = 0.221,0.138, P> 0.1). Conclusion Serum OPG concentration has important clinical value in differentiating PCa and BPH. There is no significant correlation between serum OPG concentration and serum PSA and prostate volume in patients with PCa.